Lilly Prozac
Fluoxetine will have six months of pediatric exclusivity beginning Feb. 2 when Lilly's patent no. 4,314,081 expires. The additional exclusivity is based on clinical data in adolescents aged seven to 17 from two pediatric depression studies, an obsessive compulsive disorder study and a pharmacokinetic study submitted to FDA. If Lilly is granted a rehearing in appeals court or a review in the Supreme Court for its invalidated Prozac patent (No. 4,626,549), which would have expired in 2004, it could delay Barr's 180 days of Waxman/Hatch exclusivity for generic fluoxetine (1"The Pink Sheet" Oct. 30, p. 14)
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.
The HHS Secretary publicly acknowledged the unusual delay of Novavax's COVID-19 vaccine licensure, but his justification was neither scientifically accurate nor legally justifiable, experts said.
A new European initiative will help trial sponsors better understand whether digitization and decentralized clinical trials of drugs generate less carbon than traditional methods.